4-benzyl-3-crotonyl-2-oxazolidinone has been researched along with Leiomyoma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Castellucci, C; Ciarmela, P; Ciavattini, A; Greco, S; Islam, MS; Janjusevic, M; Petraglia, F; Toti, P | 1 |
1 other study(ies) available for 4-benzyl-3-crotonyl-2-oxazolidinone and Leiomyoma
Article | Year |
---|---|
Locostatin, a disrupter of Raf kinase inhibitor protein, inhibits extracellular matrix production, proliferation, and migration in human uterine leiomyoma and myometrial cells.
Topics: Antineoplastic Agents; Cell Movement; Cell Proliferation; Extracellular Matrix; Extracellular Signal-Regulated MAP Kinases; Female; Glycogen Synthase Kinase 3 beta; Humans; Leiomyoma; Myocytes, Smooth Muscle; Myometrium; Oxazolidinones; Phosphatidylethanolamine Binding Protein; Phosphorylation; Signal Transduction; Tumor Cells, Cultured; Uterine Neoplasms | 2016 |